NASDAQ:AEZS - AEterna Zentaris Stock Price, Price Target & More

$1.61 +0.05 (+3.21 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$1.61
Today's Range$1.53 - $1.6390
52-Week Range$0.78 - $3.75
Volume72,554 shs
Average Volume388,603 shs
Market Capitalization$25.65 million
P/E Ratio-1.19
Dividend YieldN/A
Beta0.92

About AEterna Zentaris (NASDAQ:AEZS)

AEterna Zentaris logoAeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. It also has a collaboration agreement with Sinopharm A-Think Pharmaceuticals Co., Ltd. for the development, manufacture, and commercialization of Zoptrex, which has completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer in the People's Republic of China. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.

Receive AEZS News and Ratings via Email

Sign-up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AEZS
CUSIPN/A
Phone843-900-3211

Debt

Debt-to-Equity RatioN/A
Current Ratio1.63%
Quick Ratio1.52%

Price-To-Earnings

Trailing P/E Ratio-1.19
Forward P/E Ratio-6.44
P/E GrowthN/A

Sales & Book Value

Annual Sales$920,000.00
Price / Sales28.77
Cash FlowN/A
Price / CashN/A
Book Value($0.17) per share
Price / Book-9.47

Profitability

EPS (Most Recent Fiscal Year)($1.35)
Net Income$-16,790,000.00
Net Margins-1,819.72%
Return on Equity-1,688.61%
Return on Assets-88.68%

Miscellaneous

Employees47
Outstanding Shares16,440,000

How to Become a New Pot Stock Millionaire

AEterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions

What is AEterna Zentaris' stock symbol?

AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

How were AEterna Zentaris' earnings last quarter?

AEterna Zentaris Inc. (NASDAQ:AEZS) released its quarterly earnings data on Wednesday, March, 28th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.13. The biopharmaceutical company earned $0.18 million during the quarter, compared to the consensus estimate of $0.14 million. AEterna Zentaris had a negative net margin of 1,819.72% and a negative return on equity of 1,688.61%. View AEterna Zentaris' Earnings History.

When is AEterna Zentaris' next earnings date?

AEterna Zentaris is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for AEterna Zentaris.

What price target have analysts set for AEZS?

2 brokerages have issued 12-month target prices for AEterna Zentaris' stock. Their predictions range from $3.00 to $4.00. On average, they anticipate AEterna Zentaris' stock price to reach $3.50 in the next year. View Analyst Ratings for AEterna Zentaris.

Who are some of AEterna Zentaris' key competitors?

Who are AEterna Zentaris' key executives?

AEterna Zentaris' management team includes the folowing people:
  • Dr. Richard Sachse, Former Sr. VP, CSO & Chief Medical Officer
  • Mr. Michael V. Ward, Chief Exec. Officer (Age 61)
  • Mr. James Clavijo, Chief Financial Officer (Age 52)
  • Mr. Paul Burroughs, Director of Communications
  • Dr. Eckhard G. Guenther, VP of Alliance Management

Has AEterna Zentaris been receiving favorable news coverage?

Headlines about AEZS stock have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AEterna Zentaris earned a media sentiment score of 0.12 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 45.99 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of AEterna Zentaris?

Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AEterna Zentaris' stock price today?

One share of AEZS stock can currently be purchased for approximately $1.61.

How big of a company is AEterna Zentaris?

AEterna Zentaris has a market capitalization of $25.65 million and generates $920,000.00 in revenue each year. The biopharmaceutical company earns $-16,790,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. AEterna Zentaris employs 47 workers across the globe.

How can I contact AEterna Zentaris?

AEterna Zentaris' mailing address is 1 PLACE VILLE MARIE SUITE 2500, MONTREAL A8, H3B 1R1. The biopharmaceutical company can be reached via phone at 843-900-3211 or via email at [email protected]


MarketBeat Community Rating for AEterna Zentaris (AEZS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  268 (Vote Outperform)
Underperform Votes:  177 (Vote Underperform)
Total Votes:  445
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe AEZS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEZS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AEterna Zentaris (NASDAQ:AEZS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for AEterna Zentaris in the last 12 months. Their average twelve-month price target is $3.50, suggesting that the stock has a possible upside of 117.39%. The high price target for AEZS is $4.00 and the low price target for AEZS is $3.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.50$3.50$3.50$4.3333
Price Target Upside: 117.39% upside38.88% upside38.88% upside150.48% upside

AEterna Zentaris (NASDAQ:AEZS) Consensus Price Target History

Price Target History for AEterna Zentaris (NASDAQ:AEZS)

AEterna Zentaris (NASDAQ:AEZS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018HC WainwrightReiterated RatingBuy$3.00LowView Rating Details
3/28/2018Maxim GroupSet Price TargetBuy$4.00MediumView Rating Details
1/8/2017Canaccord GenuitySet Price TargetBuy$7.50 -> $6.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

AEterna Zentaris (NASDAQ:AEZS) Earnings History and Estimates Chart

Earnings by Quarter for AEterna Zentaris (NASDAQ:AEZS)

AEterna Zentaris (NASDAQ:AEZS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.25 EPS
Next Year EPS Consensus Estimate: $0.37 EPS

AEterna Zentaris (NASDAQ AEZS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018        
3/28/2018Q4 2017($0.37)($0.24)$0.14 million$0.18 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.41)($0.44)$0.24 millionViewN/AView Earnings Details
8/10/20176/30/2017($0.41)($0.46)$0.22 million$0.24 millionViewN/AView Earnings Details
5/8/20173/31/2017($0.33)($0.31)$0.85 million$0.26 millionViewListenView Earnings Details
3/15/201712/31/2016($0.73)($0.71)$0.40 million$0.30 millionViewN/AView Earnings Details
11/8/2016Q316($0.74)($0.61)$0.22 million$0.27 millionViewListenView Earnings Details
8/9/2016Q2 2016($1.19)($0.71)$0.10 millionViewN/AView Earnings Details
5/9/2016Q216($0.82)($0.71)$0.50 million$0.24 millionViewN/AView Earnings Details
3/29/2016Q415($1.30)($1.46)$0.25 million$0.10 millionViewN/AView Earnings Details
11/5/2015Q315($0.06)($0.07)$0.20 million$0.17 millionViewN/AView Earnings Details
8/13/2015Q215($0.08)($0.14)$0.55 million$0.20 millionViewListenView Earnings Details
5/7/2015Q1 2015($0.10)($0.13)$0.07 millionViewN/AView Earnings Details
3/17/2015Q414($0.16)$0.06$0.01 millionViewN/AView Earnings Details
11/4/2014Q3 2014($20.00)ViewN/AView Earnings Details
8/7/2014Q2 2014($9.00)ViewN/AView Earnings Details
5/8/2014Q1 2014($8.00)ViewN/AView Earnings Details
3/20/2014Q413($0.04)($0.22)$12.41 millionViewN/AView Earnings Details
11/5/2013Q3 2013($26.00)$13.00$2.22 million$21.06 millionViewN/AView Earnings Details
8/8/2013Q2 2013($28.00)$37.00$8.35 million$30.09 millionViewN/AView Earnings Details
5/7/2013Q1 2013($29.00)$7.00$16.60 millionViewN/AView Earnings Details
3/21/2013Q412($0.31)($0.29)$7.96 million$9.16 millionViewN/AView Earnings Details
11/13/2012Q312($0.43)($0.35)$8.38 million$7.10 millionViewN/AView Earnings Details
8/14/2012Q2 2012($41.99)($34.19)ViewN/AView Earnings Details
5/9/2012Q1 2012($53.99)($64.79)ViewN/AView Earnings Details
3/27/2012Q4 2011($53.99)($41.99)ViewN/AView Earnings Details
11/10/2011Q3 2011($53.99)$6.60ViewN/AView Earnings Details
8/10/2011Q2 2011($47.99)($70.19)ViewN/AView Earnings Details
5/18/2011Q1 2011($53.99)($58.19)ViewN/AView Earnings Details
3/22/2011Q4 2010($41.99)($18.00)ViewN/AView Earnings Details
11/9/2010Q3 2010($59.99)($73.19)ViewN/AView Earnings Details
8/12/2010Q2 2010($59.99)($36.59)ViewN/AView Earnings Details
5/13/2010Q1 2010($71.99)($55.79)ViewN/AView Earnings Details
3/24/2010Q4 2009($107.98)$116.38ViewN/AView Earnings Details
11/11/2009Q3 2009($119.98)($115.78)ViewN/AView Earnings Details
8/11/2009Q2 2009($137.97)($146.37)ViewN/AView Earnings Details
5/6/2009Q1 2009($89.98)($139.77)ViewN/AView Earnings Details
3/11/2009Q4 2008($161.97)($161.97)ViewN/AView Earnings Details
11/13/2008Q3 2008($161.97)($156.57)ViewN/AView Earnings Details
8/12/2008Q2 2008($161.97)($232.15)ViewN/AView Earnings Details
5/7/2008Q1 2008($137.97)($122.38)ViewN/AView Earnings Details
3/5/2008Q4 2007($113.98)($155.97)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AEterna Zentaris (NASDAQ:AEZS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

AEterna Zentaris (NASDAQ AEZS) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 1.91%
Insider Trading History for AEterna Zentaris (NASDAQ:AEZS)
Insider Trading History for AEterna Zentaris (NASDAQ:AEZS)

AEterna Zentaris (NASDAQ AEZS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

AEterna Zentaris (NASDAQ AEZS) News Headlines

Source:
DateHeadline
 AEterna Zentaris Inc. (AEZS) Receives Consensus Recommendation of "Strong Buy" from Brokerages AEterna Zentaris Inc. (AEZS) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - April 20 at 3:12 AM
Aeterna Zentaris Files Management Information CircularAeterna Zentaris Files Management Information Circular
finance.yahoo.com - April 9 at 10:53 AM
AEterna Zentaris (AEZS) Downgraded by Zacks Investment Research to HoldAEterna Zentaris (AEZS) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 6 at 4:14 PM
AEterna Zentaris (AEZS) Upgraded to "Buy" at Zacks Investment ResearchAEterna Zentaris (AEZS) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 5 at 4:06 PM
 AEterna Zentaris Inc. (AEZS) Receives Consensus Recommendation of "Strong Buy" from Analysts AEterna Zentaris Inc. (AEZS) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - April 5 at 3:34 PM
Aeterna Zentaris (AEZS) CEO Michael Ward on Q4 2017 Results - Earnings Call TranscriptAeterna Zentaris' (AEZS) CEO Michael Ward on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 30 at 3:35 PM
HC Wainwright Analysts Give AEterna Zentaris (AEZS) a $3.00 Price TargetHC Wainwright Analysts Give AEterna Zentaris (AEZS) a $3.00 Price Target
www.americanbankingnews.com - March 29 at 3:36 PM
AEterna Zentaris (AEZS) Given a $4.00 Price Target at Maxim GroupAEterna Zentaris (AEZS) Given a $4.00 Price Target at Maxim Group
www.americanbankingnews.com - March 28 at 1:32 PM
AEterna Zentaris beats by $0.28, beats on revenueAEterna Zentaris beats by $0.28, beats on revenue
seekingalpha.com - March 28 at 10:37 AM
ValuEngine Upgrades AEterna Zentaris (AEZS) to HoldValuEngine Upgrades AEterna Zentaris (AEZS) to Hold
www.americanbankingnews.com - March 25 at 9:16 PM
AEterna Zentaris (AEZS) to Release Quarterly Earnings on TuesdayAEterna Zentaris (AEZS) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 24 at 12:52 AM
Aeterna Zentaris to Announce Fourth Quarter and Year End 2017 Financial and Operating Results on March 28th, 2018Aeterna Zentaris to Announce Fourth Quarter and Year End 2017 Financial and Operating Results on March 28th, 2018
finance.yahoo.com - March 22 at 10:31 AM
Aeterna Zentaris (AEZS) Appoints James Clavijo as CFOAeterna Zentaris (AEZS) Appoints James Clavijo as CFO
www.streetinsider.com - March 6 at 10:53 AM
Aeterna Zentaris (AEZS) Provides Update on Class Action Lawsuit - StreetInsider.comAeterna Zentaris (AEZS) Provides Update on Class Action Lawsuit - StreetInsider.com
www.streetinsider.com - March 5 at 10:59 AM
AEterna Zentaris (AEZS) Downgraded by ValuEngineAEterna Zentaris (AEZS) Downgraded by ValuEngine
www.americanbankingnews.com - March 5 at 12:48 AM
Analyzing AEterna Zentaris (AEZS) & Checkpoint Therapeutics (CKPT)Analyzing AEterna Zentaris (AEZS) & Checkpoint Therapeutics (CKPT)
www.americanbankingnews.com - February 27 at 1:36 AM
Head-To-Head Contrast: AEterna Zentaris (AEZS) & Esperion Therapeutics (ESPR)Head-To-Head Contrast: AEterna Zentaris (AEZS) & Esperion Therapeutics (ESPR)
www.americanbankingnews.com - February 20 at 9:12 PM
Biotech Forum Daily Digest For January 18thBiotech Forum Daily Digest For January 18th
seekingalpha.com - February 13 at 3:17 PM
AEterna Zentaris (AEZS) Downgraded by Zacks Investment ResearchAEterna Zentaris (AEZS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 29 at 5:00 PM
AEterna Zentaris Inc. (AEZS) Short Interest UpdateAEterna Zentaris Inc. (AEZS) Short Interest Update
www.americanbankingnews.com - January 29 at 1:20 AM
AEterna Zentaris (AEZS) Upgraded at Zacks Investment ResearchAEterna Zentaris (AEZS) Upgraded at Zacks Investment Research
www.americanbankingnews.com - January 26 at 4:54 PM
AEterna Zentaris: Licensing Agreement Takes Out Dilution Risk - Seeking AlphaAEterna Zentaris: Licensing Agreement Takes Out Dilution Risk - Seeking Alpha
seekingalpha.com - January 24 at 3:18 PM
Biotech Stocks Research Reports Released on 22nd Century, Abeona Therapeutics, Acasti Pharma, and Aeterna ... - PR Newswire (press release)Biotech Stocks' Research Reports Released on 22nd Century, Abeona Therapeutics, Acasti Pharma, and Aeterna ... - PR Newswire (press release)
www.prnewswire.com - January 24 at 7:55 AM
5 Great Breakout Stocks Offering Superlative Returns5 Great Breakout Stocks Offering Superlative Returns
finance.yahoo.com - January 18 at 3:20 PM
Mid-Day Market Update: Dow Surges Over 150 Points; HTG ... - BenzingaMid-Day Market Update: Dow Surges Over 150 Points; HTG ... - Benzinga
www.benzinga.com - January 18 at 6:56 AM
Aeterna Zentaris Inc. Surges After Agreement With Strongbridge - Baystreet.caAeterna Zentaris Inc. Surges After Agreement With Strongbridge - Baystreet.ca
www.baystreet.ca - January 18 at 6:56 AM
44 Biggest Movers From Yesterday - Benzinga44 Biggest Movers From Yesterday - Benzinga
www.benzinga.com - January 18 at 6:56 AM
Aeterna Zentaris shares halted pending news - Seeking AlphaAeterna Zentaris shares halted pending news - Seeking Alpha
seekingalpha.com - January 18 at 6:56 AM
NVS Kymriah To Face FDA Again, AEZS Teams Up With SBBP, A Rival For EXAS? - NasdaqNVS' Kymriah To Face FDA Again, AEZS Teams Up With SBBP, A Rival For EXAS? - Nasdaq
www.nasdaq.com - January 18 at 6:56 AM
AEterna Zentaris (AEZS) PT Set at $4.00 by Maxim GroupAEterna Zentaris (AEZS) PT Set at $4.00 by Maxim Group
www.americanbankingnews.com - January 17 at 11:26 PM
Aeterna Zentaris shares halted pending newsAeterna Zentaris shares halted pending news
seekingalpha.com - January 17 at 7:25 AM
AEterna Zentaris (AEZS) Upgraded to Buy at Zacks Investment ResearchAEterna Zentaris (AEZS) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - January 16 at 4:36 PM
AEterna Zentaris (AEZS) Downgraded to "Hold" at Zacks Investment ResearchAEterna Zentaris (AEZS) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 4:28 PM
Aeterna Zentaris Inc. (AEZS)Aeterna Zentaris Inc. (AEZS)
finance.yahoo.com - January 11 at 3:19 PM
Stocks push slightly higher, President Trump prepares to sign tax bill into lawStocks push slightly higher, President Trump prepares to sign tax bill into law
finance.yahoo.com - December 23 at 8:33 PM
Aeterna Zentaris (AEZS) Offers Update on Litigation against David Dodd and Philip Theodore - StreetInsider.comAeterna Zentaris (AEZS) Offers Update on Litigation against David Dodd and Philip Theodore - StreetInsider.com
www.streetinsider.com - December 23 at 1:37 AM
Aeterna Zentaris Provides Update on Litigation against David Dodd and Philip TheodoreAeterna Zentaris Provides Update on Litigation against David Dodd and Philip Theodore
feeds.benzinga.com - December 22 at 5:48 PM
Aeterna Zentaris (AEZS) Reports FDA Approval of Macrilen for Diagnosis of AGHDAeterna Zentaris (AEZS) Reports FDA Approval of Macrilen for Diagnosis of AGHD
www.streetinsider.com - December 21 at 3:19 PM
(AEZS) (NQ) Higher; (PCG) (BBBY) - StreetInsider.com - StreetInsider.com(AEZS) (NQ) Higher; (PCG) (BBBY) - StreetInsider.com - StreetInsider.com
www.streetinsider.com - December 21 at 3:19 PM
Mid-Afternoon Market Update: Aeterna Zentaris Climbs Following FDA Approval Of Macrilen; Apogee Shares Slide - BenzingaMid-Afternoon Market Update: Aeterna Zentaris Climbs Following FDA Approval Of Macrilen; Apogee Shares Slide - Benzinga
www.benzinga.com - December 21 at 3:19 PM
IIROC Trade Resumption - Aeterna Zentaris Inc.IIROC Trade Resumption - Aeterna Zentaris Inc.
finance.yahoo.com - December 21 at 3:19 PM
Aeterna Zentaris stock soars toward 8-month high after Macrilen granted marketing approvalAeterna Zentaris' stock soars toward 8-month high after Macrilen granted marketing approval
finance.yahoo.com - December 21 at 3:19 PM
After-Hours Stock Movers 12/20: (AEZS) (VERI) (CORT) Higher; (PCG) (BBBY) Lower (more...) - StreetInsider.comAfter-Hours Stock Movers 12/20: (AEZS) (VERI) (CORT) Higher; (PCG) (BBBY) Lower (more...) - StreetInsider.com
www.streetinsider.com - December 21 at 6:25 AM
Aeterna Zentaris (AEZS) Reports FDA Approval of Macrilen for Diagnosis of AGHD - StreetInsider.comAeterna Zentaris (AEZS) Reports FDA Approval of Macrilen for Diagnosis of AGHD - StreetInsider.com
www.streetinsider.com - December 21 at 6:25 AM
Canadas Aeterna gets FDA approval for growth hormone deficiency testCanada's Aeterna gets FDA approval for growth hormone deficiency test
finance.yahoo.com - December 21 at 6:25 AM
Aeterna Zentaris Announces FDA Approval of Macrilen™ (macimorelin) for Diagnosis of Adult Growth Hormone DeficiencyAeterna Zentaris Announces FDA Approval of Macrilen™ (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency
finance.yahoo.com - December 21 at 6:25 AM
IIROC Trade Halt - Aeterna Zentaris Inc.IIROC Trade Halt - Aeterna Zentaris Inc.
finance.yahoo.com - December 21 at 6:25 AM
AEterna Zentaris Inc. (USA) (AEZS) Investors Celebrate FDA Approval; Shares SkyrocketAEterna Zentaris Inc. (USA) (AEZS) Investors Celebrate FDA Approval; Shares Skyrocket
finance.yahoo.com - December 21 at 6:25 AM
Aeterna Zentaris trading halted pending newsAeterna Zentaris trading halted pending news
seekingalpha.com - December 20 at 9:21 PM
FDA OKs Aeterna Zentaris Macrilen for diagnosis of adult growth hormone deficiency; shares up 53% after hoursFDA OKs Aeterna Zentaris' Macrilen for diagnosis of adult growth hormone deficiency; shares up 53% after hours
seekingalpha.com - December 20 at 9:21 PM

SEC Filings

AEterna Zentaris (NASDAQ:AEZS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AEterna Zentaris (NASDAQ:AEZS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AEterna Zentaris (NASDAQ AEZS) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.